BioSpace News Archive

FDA

ViiV’s Tivicay Approved for Children as Young as 4 Weeks with HIV

The U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay PD (dolutegravir) in combination with other antiretroviral drugs for children with HIV.

June 15, 2020
·
3 min read
·
Mark Terry
Job Trends

AstraZeneca Strikes Deal with European Nations to Supply 400 Million Doses of COVID-19 Vaccine

The U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020 – if it clears the clinic.

June 15, 2020
·
3 min read
·
Alex Keown
Business

Magenta Enters Collaboration Agreement with Beam to Further Explore MGTA-117

The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.

June 15, 2020
·
3 min read
·
Krystle Vermes
FDA

FDA Cancels Emergency Use Authorization of Hydroxychloroquine for COVID-19

The FDA indicated that, based on new evidence, there was not enough supporting evidence for the two drugs to be considered effective in treating COVID-19.

June 15, 2020
·
3 min read
·
Mark Terry
Policy

Biopharma Update on the Novel Coronavirus: June 15

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.

June 15, 2020
·
3 min read
·
BioSpace Editorial Staff
Business

Stem Cell Reprogramming Company Bit Bio Rakes in $41.5 Million in Series A

Bit Bio’s aim is to decode “cellular identity” in order to generate every cell type of the human body.

June 15, 2020
·
2 min read
·
Alex Keown
Drug Development

Sinovac Biotech’s COVID-19 Vaccine Shows Positive Early Results

Sinovac Biotech announced positive early data from a Phase I/II clinical trial of its COVID-19 vaccine, CoronaVac. The vaccine showed both favorable immunogenicity and safety.

June 15, 2020
·
3 min read
·
Mark Terry
Drug Development

Eli Lilly Begins Phase III Study of RA Drug to Treat COVID-19

Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.

June 15, 2020
·
2 min read
·
Alex Keown
BioMidwest

AbbVie’s Venclexta and Chemo Combination Decreases Death by 34% in AML

AbbVie reported positive results from the VIALE-A clinical trial of Venclexta plus azacytidine in previously untreated acute myeloid leukemia (AML) patients who were ineligible for intensive chemotherapy.

June 15, 2020
·
2 min read
·
Mark Terry
Policy

Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.

June 15, 2020
·
5 min read